Ceres Oncology Pty Ltd is a clinical-stage biopharmaceutical company developing therapies that target blood and lymphatic vessels in the oncology setting. Blood vessel growth (angiogenesis) and lymphatic vessel growth (lymphangiogenesis) are important targets for anti-cancer therapies as both processes are involved in tumouror progression. Anti-angiogenic antibodies and small molecules prolong life in cancer patients, but are not as effective as anticipated due to primary non-response and treatment escape. Ceres Oncology is focused on the development of a new class of antibodies in the anti-angiogenic market and has an exclusive, worldwide licence to oncology applications of vascular endothelial growth factor (VEGF)-C antibodies. The company is a wholly-owned subsidiary of and has received seed funding from Circadian Technologies Limited.